A detailed history of Smith Anglin Financial, LLC transactions in Pfizer Inc stock. As of the latest transaction made, Smith Anglin Financial, LLC holds 20,554 shares of PFE stock, worth $575,100. This represents 0.06% of its overall portfolio holdings.

Number of Shares
20,554
Previous 9,838 108.92%
Holding current value
$575,100
Previous $283,000 101.41%
% of portfolio
0.06%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024

BUY
$25.89 - $29.73 $277,437 - $318,586
10,716 Added 108.92%
20,554 $570,000
Q4 2023

Jan 17, 2024

SELL
$26.13 - $33.94 $68,120 - $88,481
-2,607 Reduced 20.95%
9,838 $283,000
Q3 2023

Oct 11, 2023

BUY
$32.09 - $37.51 $4,364 - $5,101
136 Added 1.1%
12,445 $412,000
Q2 2023

Jul 10, 2023

BUY
$36.12 - $41.79 $120,749 - $139,703
3,343 Added 37.29%
12,309 $451,000
Q1 2023

Apr 11, 2023

BUY
$39.39 - $51.28 $1,418 - $1,846
36 Added 0.4%
8,966 $365,000
Q4 2022

Feb 14, 2023

SELL
$41.75 - $54.5 $24,298 - $31,719
-582 Reduced 6.12%
8,930 $457,000
Q3 2022

Oct 24, 2022

SELL
$43.76 - $53.42 $1,050 - $1,282
-24 Reduced 0.25%
9,512 $416,000
Q2 2022

Jul 25, 2022

BUY
$46.53 - $55.17 $1,302 - $1,544
28 Added 0.29%
9,536 $500,000
Q1 2022

May 16, 2022

SELL
$45.75 - $56.69 $25,711 - $31,859
-562 Reduced 5.58%
9,508 $492,000
Q4 2021

Jan 31, 2022

BUY
$41.32 - $61.25 $198,088 - $293,632
4,794 Added 90.86%
10,070 $595,000
Q3 2021

Oct 20, 2021

SELL
$39.25 - $50.42 $14,287 - $18,352
-364 Reduced 6.45%
5,276 $227,000
Q2 2021

Aug 10, 2021

BUY
$35.91 - $40.68 $202,532 - $229,435
5,640 New
5,640 $221,000
Q1 2021

Jul 08, 2021

SELL
$33.49 - $37.77 $207,403 - $233,909
-6,193 Closed
0 $0
Q4 2020

Jul 08, 2021

BUY
$33.47 - $42.56 $207,279 - $263,574
6,193 New
6,193 $228,000

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $157B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Smith Anglin Financial, LLC Portfolio

Follow Smith Anglin Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith Anglin Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Smith Anglin Financial, LLC with notifications on news.